Method for preparing a K serum with a vibrio parahaemolyticus as an antigen

Abstract

A novel K (capsular antigen) serotype of Vibrio parahaemolyticus and an application thereof are provided. A novel K (capsular antigen) serotype of Vibrio parahaemolyticus, which was deposited at the China General Microbiological Culture Collection Center (Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing) on Feb. 20, 2019, with a deposit number of CGMCC No. 17249, wherein the K epitope of the Vibrio parahaemolyticus has a sequence set forth in Sequence No. 1. The novel K serum is highly specific, and can be used to conveniently and quickly detect a novel K serotype of Vibrio parahaemolyticus (O4:KUT-recAin) which has a rising infection rate in recent years. It provides important detection techniques for the pathogen diagnosis, monitoring and prevention of infectious diarrhea.

Claims

1. A method for preparing a K serum with a Vibrio parahaemolyticus as an antigen, comprising: the Vibrio parahaemolyticus is seeded into a BHI medium with 3% NaCl, and cultured at 37° C. overnight; the bacteria are collected, washed twice with normal saline, and then inactivated with a normal saline solution containing 0.5% formaldehyde for 24 h, and the inactivated bacteria are then dissolved in normal saline to act as an antigen; and the K serum is prepared by injecting and immunizing an animal with the Vibrio parahaemolyticus as the antigen; wherein the Vibrio parahaemolyticus was deposited at the China General Microbiological Culture Collection Center (Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing) on Feb. 20, 2019, with a deposit number of CGMCC No. 17249, wherein the K epitope of the Vibrio parahaemolyticus has a sequence set forth in Sequence No. 1.

2. The method for preparing the K serum with a Vibrio parahaemolyticus as an antigen according to claim 1, further comprising: healthy 12-week-old New Zealand white rabbits are selected and immunized with the inactivated Vibrio parahaemolyticus in 0.85% NaCl at a concentration of 109 CFU/ml, 4 sites for each rabbit and 250 μl for each site, and subsequently boosted once every 2 weeks in an immunization volume the same as the first immunization, 5 times in total; thereafter, whole blood is collected from the heart, and the collected whole blood is left at 37° C. for 2 h, transferred to 4° C. overnight, and then centrifuged to collect serum, which is the K serum.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

(1) FIG. 1 is the results of similarity comparison between the K epitope sequence of Vibrio parahaemolyticus O4:KUT-recAin strain and 37 known K epitope sequences;

(2) FIG. 2 shows the growth morphology of the Vibrio parahaemolyticus O4:KUT-recAin strain on a plate. The left picture shows the TCBS plate, and the right picture shows the Columbia blood agar plate;

(3) FIG. 3 is the morphology of the colonies of the Vibrio parahaemolyticus O4:KUT-recAin strain under a microscope after Gram staining;

(4) FIG. 4 is a growth curve of the Vibrio parahaemolyticus O4: KUT-recAin strain;

(5) FIG. 5 shows the data of diarrhea and death in newborn rabbits fed with the Vibrio parahaemolyticus O4:KUT-recAin strain;

(6) FIG. 6 shows the agglutination reaction of the immune serum for the Vibrio parahaemolyticus O4:KUT-recAin strain with 33 known K serotype strains;

(7) FIG. 7 shows that the immune serum for the Vibrio parahaemolyticus O4:KUT-recAin strain absorbed with the K24 strain inactivated by 0.5% formaldehyde does not agglutinate with the K24 strain;

(8) FIG. 8 shows the agglutination reaction between the novel K serum and the Vibrio parahaemolyticus O4:KUT-recAin strain (middle). Left: 0.85% NaCl and Vibrio parahaemolyticus O4:KUT-recAin strains; right: the novel K serum and the O3:K6 serotype strain.

DETAILED DESCRIPTION

(9) The present invention will be further described below with reference to specific examples. It should be understood that these examples are only used to illustrate rather than limit the present invention. The following examples are not used to limit the protection scope of the present invention.

Example 1 Isolation, Identification and Virulence Test of a Novel K (Capsular Antigen) Serotype of Vibrio parahaemolyticus (O4:KUT-recAin)

(10) Fecal specimens from patients with acute diarrhea were introduced into alkaline peptone water, cultured for enrichment at 37° C. for 6 h, and then transferred to a TCBS medium to incubate at 37° C. for 18 h. Single colonies were selected and identified as Vibrio parahaemolyticus by a Bruker matrix-assisted laser desorption ionization-time of flight (MALDI TOF) mass spectrometer. The serotype of Vibrio parahaemolyticus was determine by the slide agglutination method using Nihon Seiken's Vibrio parahaemolyticus diagnostic sera (including 11 O and 69 K), with 0.85% normal saline as a negative control. Vibrio parahaemolyticus strains that did not agglutinate with the existing 69 types of K sera were marked as KUT.

(11) The whole genome of the KUT strains was sequenced, and their K epitopes were analyzed to further determine that whether they are novel K serotypes of Vibrio parahaemolyticus. The present invention provides a novel K serotype of Vibrio parahaemolyticus that agglutinates with O4 sera but does not agglutinate with the existing 69 kinds of K sera, named O4:KUT-recAin strain, which was deposited at the China General Microbiological Culture Collection Center (CGMCC for short) in Beijing, China on Feb. 20, 2019 with a deposit number of CGMCC No. 17249.

(12) Whole genome sequencing analysis of the K epitope of the Vibrio parahaemolyticus O4:KUT-recAin strain found that the sequence of K epitope (see sequence 1) of this strain was different from those of current K epitopes of V. parahaemolyticus in the NCBI database. This further proved that this Vibrio parahaemolyticus is a new strain of K serotype. The similarity comparison results of the sequence of K epitope of the Vibrio parahaemolyticus O4:KUT-recAin strain with those of 37 known K epitopes are shown in FIG. 1.

(13) The growth morphology of the Vibrio parahaemolyticus O4:KUT-recAin strain on a plate is shown in FIG. 2. Well-grown colonies were picked and seeded in a BHI medium with 3% NaCl (pH=8.5) to culture at 37° C. See FIG. 4 for the growth curve. The culture characteristics of the O4:KUT-recAin strain in FIG. 4 show that the OD600 nm value of the solution started to increase about 2 h after inoculation, and reached the maximum between 14-16 h, but then began to decline with time.

(14) The Vibrio parahaemolyticus O4:KUT-recAin strain at 1×1010 CFUs was fed to 2-day-old newborn rabbits. After 20 h, the newborn rabbits developed symptoms of diarrhea, and in severe cases, suffered weight loss and even death. FIG. 5 shows the diarrhea and death data of 5 litter rabbits, 37 in total, fed with the Vibrio parahaemolyticus O4:KUT-recAin strain. The diarrhea rate of the newborn rabbits was 41% after 2 days, and reached 60% after 5 days. Eight days after infection, the mortality of the newborn rabbits was 35%.

Example 2 Preparation of a Novel K Serum for Vibrio parahaemolyticus

(15) Preparation of antigen: the novel K serotype of Vibrio parahaemolyticus O4: KUT-recAin strain was seeded into a BHI medium with 3% NaCl to incubate at 37° C. overnight, centrifuged at 3000×g for 10 min to collect the bacteria. The bacteria were washed twice with normal saline, and then inactivated with normal saline containing 0.5% formaldehyde for 24 h, and centrifuged at 3000×g for 10 min to collect the inactivated bacteria. Finally, the inactivated bacteria were dissolved in normal saline for immunization of rabbits.

(16) Immunization of rabbits: 3 healthy 12-week-old New Zealand white rabbits were acclimatized for 3 days and then immunized with the inactivated novel K serotype of Vibrio parahaemolyticus dissolved in 0.85% NaCl (109 CFU/ml), 4 sites (left and right sides of the back and thigh roots) for each rabbit, 250 μl for each site. The immunization was boosted once every 2 weeks in an immunization volume the same as the first immunization, 5 times in total; thereafter, the whole blood was collected from the heart.

(17) Collection of immune serum: The collected whole blood was left at 37° C. for 2 h, transferred to 4° C. overnight, and then centrifuged at 12000×g for 10 min the next day to collect serum, which was the immune serum.

(18) Preparation of specific immune serum: The collected immune serum was subjected to a slide agglutination reaction with the novel K serotype strain. The specific steps for slide agglutination are as follows: The slide was streaked into sections using a marker and one drop (about 5 μl) of the novel K serum was added dropwise into each section, wherein in one section, normal saline was used instead of the novel K serum as a control to exclude self-agglutination. Then, 5 μl of the bacterial suspension was added to each section, and the reaction was thoroughly mixed for 1 min to observe whether there was agglutination. The agglutination of the immune serum with the novel K serotype strain was obvious. The immune serum for the novel K serotype strain cross-reacted with the K 24, K 59, and K 61 serotype strains among the known K serotype strains (FIG. 6). The immune serum was sequentially adsorbed with 109 CFU/ml K24 strain, K61 strain, and K59 strain inactivated with 0.5% formaldehyde at 4° C. for 2-24 h, and then centrifuged at 12000×g for 10 min to obtain a supernatant which was the immune serum specific to the novel K serotype strain (FIG. 7), called the novel K serum.

Example 3 Properties of the Novel K Serum

(19) The novel K serum and KUT strains were able to quickly detect the novel K serotype strain (O4:KUT-recAin) by agglutination (FIG. 8). The novel K serum did not agglutinate with 33 known K serotypes of Vibrio parahaemolyticus (Table 1), and did not agglutinate with enteric pathogens including Vibrio cholerae, Vibrio fluvialis, Campylobacter jejuni, Campylobacter coli, Escherichia coli, Salmonella typhimurium, Salmonella typhi, Shigella dysenteriae, and Shigella flexneri either (Table 2). When diluted 64-fold with normal saline by the doubling dilution method, the novel K serum still obviously agglutinated with the novel K serotype strain (O4:KUT-recAin) (Table 3). The novel K serum has good specificity and sensitivity.

(20) TABLE-US-00001 TABLE 1 Agglutination of the novel K serum with different K serotypes of Vibrio parahaemolyticus Vibrio parahaemolyticus No. strain K serotype Agglutination  1 VP2355 K3  No  2 VP378  K4  No  3 VP857  K5  No  4 VP91  K6  No  5 VP30  K8  No  6 VP473  K9  No  7 VP3125 K13 No  8 VP401  K17 No  9 VP797  K18 No 10 VP1943 K20 No 11 VP948  K23 No 12 VP2022 K24 No 13 VP78  K25 No 14 VP2481 K28 No 15 VP74  K29 No 16 VP2012 K30 No 17 VP1906 K34 No 18 VP146  K36 No 19 VP2626 K38 No 20 VP2838 K41 No 21 VP563  K42 No 22 VP649  K44 No 23 VP53  K46 No 24 VP2368 K48 No 25 VP412  K53 No 26 VP792  K55 No 27 VP192  K56 No 28 VP482  K57 No 29 VP58  K59 No 30 VP3116 K60 No 31 VP2406 K61 No 32 VP2399 K64 No 33 VP544  K68 No

(21) TABLE-US-00002 TABLE 2 Agglutination of the novel K serum with other intestinal pathogens No. Bacteria Agglutination 1 Vibrio cholerae No 2 Vibrio fluvialis No 3 Campylobacter jejuni No 4 Campylobacter coli No 5 Escherichia coli No 6 Salmonella typhimurium No 7 Salmonella typhi No 8 Shigella dysenteriae No 9 Shigella flexneri No

(22) TABLE-US-00003 TABLE 3 Agglutination of the novel K serum (doubling diluted) with the novel K serotype of Vibrio parahaemolyticus Agglutination with the novel K serotype of Serum Vibrio parahaemolyticus (109 CFU/ml) Pre-immune serum 1:1 No Novel K serum 1:2 Yes Novel K serum 1:4 Yes Novel K serum 1:8 Yes Novel K serum 1:16 Yes Novel K serum 1:32 Yes Novel K serum 1:64 Yes Novel K serum 1:128 No

Example 4 Application of the Novel K Serum

(23) Under the support of the project of Study on the Epidemic Pattern of Infectious Diseases in Zhejiang and Surrounding Provinces (2017ZX10103008), which is one of the major national R&D projects involving prevention and treatment of major infectious diseases such as AIDS and viral hepatitis in “Thirteenth Five-Year Plan”, 2368 strains of Vibrio parahaemolyticus from patients with acute diarrhea in Zhejiang, Jiangsu, Liaoning, Shenzhen, Shanghai and other places were collected in 2013-2017 and were subjected to slide agglutination test with the prepared novel K serum. A total of 329 novel K serotype strains (O4:KUT-recAin) were identified. Whole genome sequencing was performed on 161 of them to analyze their K epitopes. The results showed that they had the same K epitope as the Vibrio parahaemolyticus O4: KUT-recAin strain, that is, they are all novel K serotype of V. parahaemolyticus (O4:KUT-recAin). The accuracy of identifying the novel K serotype of Vibrio parahaemolyticus (O4:KUT-recAin) by the slide agglutination method using the prepared novel K serum was 100%. Therefore, the novel K serum can quickly and easily identify the novel K serotype of Vibrio parahaemolyticus (O4: KUT-recAin).